ChronTechs rights offering of shares and convertibles oversubscribed

The result regarding ChronTech Pharma AB’s rights offering of shares and
convertibles shows that the offering for subscribing for shares was
oversubscribed by more than 100 % and that the offering for convertibles was
slightly oversubscribed.
The board of ChronTech Pharma AB decided on the 2nd of September, 2013 with the
support of the authorization of the AGM about the present rights offering. One
share gave two separate subscription rights, one concerning the subscription for
one share at 0.03 SEK (totally 100,862,727 shares) and one concerning the
subscription of one convertible at 0.06 SEK (totally 100,862,727 convertibles).
The result shows that the offering for subscription of shares was oversubscribed
by more than 100 %, and that the offering for convertibles was slightly
oversubscribed. The two offerings will give 9 million SEK to the company before
emission costs.

”This good outcome of the offering and the positive results with our injection
technology IVIN, which were clearly above our expectations and which were
communicated last week, allows for an exciting new start for the company. The
addition of capital in combination with that the deal with Avac Ltd now has been
completed and that our costs have been reduced substantially now allow us to
concentrate on developing IVIN and our vaccine against hepatitis D. Both these
projects also have a much shorter way to market and are less costly to develop
than a candidate medicine. Our goal is to be in the clinic with IVIN already
during the next year. The board is working on an analysis of the economic
potential for IVIN”, says ChronTech’s CEO Anders Vahlne.

Those who subscribed will be allotted shares and convertibles according to the
principles in “The invitation to subscribe”. Transaction notes to those persons
who have subscribed for shares and convertibles without rights are estimated to
be issued around the 2 of October 2013. Only those who have been allotted shares
or convertibles will be notified.

As soon as the increase in share capital has been registered with the Swedish
Companies Registration Office (“Bolagsverket”), paid subscribed shares (BTAs)
and paid subscribed convertibles (BTUs) will be converted to shares and
convertibles, respectively. Trade in the new shares is estimated to begin on
First North by the end of October, 2013. The convertibles will not be up for
trading.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@chrontech.se

About ChronTech

ChronTech has developed and further develops a patent pending new type of
injection needle for a more effective uptake of genetic vaccines (IVIN) and
vaccine and therapy for hepatitis D. ChronTech also have part ownership in the
new platform technology RAS®. The ChronTech share is admitted to trade on First
North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.